Karo Bio chooses Elsevier's Reaxys products

Elsevier has announced that Karo Bio, which develops drugs for large medical needs, has started to use its Reaxys and Reaxys Medicinal Chemistry products. Karo Bio says it has chosen the solutions to support its chemists in their research and development objectives, ensuring that they have quick and easy access to state-of-the-art chemistry information.

'Not only do our chemists have access to more data, including biological as well as chemical information, but the content is more applicable to their research. We expect the availability of the Reaxys Medicinal Chemistry information alone will reduce research and development time by approximately 20 per cent,' said Maria Sjöberg, chief scientific officer at Karo Bio.

Reaxys encompasses content from over 16,000 periodicals and is claimed to have the deepest and richest fact-base of experimentally measured chemistry data. Reaxys Medicinal Chemistry offers access to data from a repository of peer-reviewed journal articles and patents and is interoperable with Reaxys.

Adding this content to Karo Bio’s information sources means that chemists will have readily available access to relevant information, according to Elsevier. That, coupled with the flexibility of the search function and the way results are presented, will enable chemists to more quickly identify and prioritise viable compounds, helping reduce the time it takes to bring innovative drugs to market, says the company.

Reaxys and Reaxys Medicinal Chemistry are part of Elsevier Life Science Solutions, a suite of interoperable, domain-specific, decision support tools that span the discovery and development workflow; including ScienceDirect, Scopus, TargetInsights, Pathway Studio, PharmaPendium Quosa and Embase.